EVO:NASDAQ
Evotec SE
1,98 US$
arrow_upward
+1,54%(+0,030) 1K
1,95 US$
arrow_downward
-1,52% (-0,030)todayBirjadan oldin
Savdolar yopilgan: 23-iyl, 16:00:01 (GMT-4) · USD
search
Barcha belgilar
1K
5K
1O
6O
YBB
1Y
5Y
MAKS
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoEVO tikeri uchun statistika yaratilmoqda...
Ochish
1,96 US$
Yuqori
1,98 US$
Past
1,95 US$
Bozor kapitali
713,58 mln
Oʻrtacha hajm
52,19 ming
Hajmi
1,67 ming
52 haftalik eng yuqori
4,42 US$
52 haftalik eng past
1,94 US$
Aksiya boʻyicha daromad
-0,62 US$
Beta
1,92
Muomaladagi aksiyalar
355,82 mln
Xodimlar soni
5 ming
Ochish
1,96 US$
Yuqori
1,98 US$
Past
1,95 US$
Bozor kapitali
713,58 mln
Oʻrtacha hajm
52,19 ming
Hajmi
1,67 ming
52 haftalik eng yuqori
4,42 US$
52 haftalik eng past
1,94 US$
Aksiya boʻyicha daromad
-0,62 US$
Beta
1,92
Muomaladagi aksiyalar
355,82 mln
Xodimlar soni
5 ming
Yangiliklar
Internetdagi manbalardan
Ad-hoc-news.de
·
2 soat oldin
Evotec stock trades steady as investors weigh pipeline progress and recent earnings trends
Ad-hoc-news.de
·
13 soat oldin
Evotec stock reflects restructuring as revenue recovers in 2024
Financial Times
·
1 kun oldin
Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management – Company Announcement
Profil
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Evotec SE haqida
AI kontentda xatolar boʻlishi mumkin. Batafsil